Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
March 16 2020 - 6:50AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced
the appointment of Kelvin Neu, M.D., to its Board of Directors.
“For over 16 years, Kelvin has been dedicated to financing and
building life science companies around the world,” said Ali
Tehrani, Ph.D., President and CEO of Zymeworks. “His clinical
knowledge and partnering expertise are a valuable complement to our
Board of Directors as we advance our lead product candidates
towards commercialization.”
Dr. Neu is a Partner at Baker Bros. Advisors LP, a long term
life-sciences investment firm. Kelvin earned his M.D. from the
Harvard Medical School-MIT Health Sciences and Technology program
after spending three years in the Immunology Ph.D. program at
Stanford University as a Howard Hughes Medical Institute Fellow.
Dr. Neu holds an A.B. (summa cum laude) from Princeton University,
where he was awarded the Khoury Prize for graduating first in his
department of Molecular Biology. He also serves as Director of
Prelude Therapeutics, Inc. and IGM Biosciences, Inc.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody
currently in Phase 2 clinical development. Zymeworks’ second
clinical candidate, ZW49, is a bispecific antibody-drug conjugate
currently in Phase 1 clinical development and combines the unique
design and antibody framework of ZW25 with Zymeworks’ proprietary
ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with nine
biopharmaceutical companies. For more information, visit
www.zymeworks.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200316005209/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com
Tiffany Tolmie (604) 678-1388 ir@zymeworks.com
Media Inquiries: Kavita Shah, Ph.D. (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024